

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Grant Wayne Heinicke et al.

Examiner:

To be assigned

Serial No.:

19/606,629

Art Unit:

1615

Filed:

06/29/2000

Docket:

For:

CONTROLLED ABSOPRTION

Dated:

November 22, 2000

DILTIAZEM

PHARMACEUTICAL FORMULATION

Assistant Commissioner for Patents Washington, DC 20231

SECOND PRELIMINARY AMENDMENT

SIR:

Please amend the above identified application as follows:

IN THE SPECIFICATION:

No changes requested.

IN THE CLAIMS:

Please cancel all pending claims.

Please add new claims 91-101 as follows:

Rule 126

60 -- A long lag pellet suitable for use in a once-a-day diffiazem formulation

comprising:

1) a core comprising an effective amount of dilliazem or a pharmaceutically

acceptable salt, the core being substantially free of organic acid;

1